Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Cowen Group
AddedMar 19, 2024
UpdatedJul 16, 2026
Cowen Group

Cowen Group

Acquired

Global investment bank providing financial services across various sectors. Serving clients in the US, UK, and Luxembourg.

Location
New York City, NY, US
Founded
1918
Firm
Compare
Portfolio
Fundraising
Employees

Investments

Aro Biotherapeutics
Aro Biotherapeutics

Total Raised

$166.5M

Rounds

4

Series B$41.5MNovember 2023
Series B$24MDecember 2022
MBrace Therapeutics
MBrace Therapeutics

Total Raised

$110M

Rounds

2

Series B$85MNovember 2023
MapLight Therapeutics
MapLight Therapeutics

Total Raised

$268.1M

Rounds

4

Series C$225MOctober 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Series Unknown$100MFebruary 2022
Torl Biotherapeutics
Torl Biotherapeutics

Total Raised

$158M

Rounds

1

Series B$158MApril 2023
Escient Pharmaceuticals
Escient Pharmaceuticals
Public

Total Raised

$237.5M

Rounds

3

Series C$120MNovember 2022
Nested Therapeutics
Nested Therapeutics

Total Raised

$125M

Rounds

2

Series A$90MOctober 2022
Autobahn Therapeutics
Autobahn Therapeutics

Total Raised

$108.7M

Rounds

2

Series Unknown$32.7MSeptember 2022
Aktis Oncology
Aktis Oncology

Total Raised

$156M

Rounds

2

Series A$84MAugust 2022
Bevi
Bevi
Series D

Total Raised

$130.3M

Rounds

13

Series D$70MAugust 2022
Delfi Diagnostics
Delfi Diagnostics

Total Raised

$330.5M

Rounds

3

Series B$225MJuly 2022
PolySign
PolySign

Total Raised

$158.2M

Rounds

8

Series C$53MApril 2022
Series B$58.5MMay 2021
Neuron23
Neuron23

Total Raised

$213.5M

Rounds

4

Series C$100MMarch 2022
2seventy bio
2seventy bio
Public

Total Raised

$315M

Rounds

4

Post Ipo Equity$170MMarch 2022
Scipher Medicine
Scipher Medicine

Total Raised

$227M

Rounds

6

Series D$110MFebruary 2022
Electra Therapeutics
Electra Therapeutics

Total Raised

$100M

Rounds

2

Series B$84MFebruary 2022
Digital Prime Technologies
Digital Prime Technologies

Total Raised

$1.9M

Rounds

9

—November 2021
Hum Capital
Hum Capital

Total Raised

$35M

Rounds

4

Series A$12MNovember 2021
Lycia Therapeutics
Lycia Therapeutics

Total Raised

$120M

Rounds

2

Series B$70MSeptember 2021
Obsidian Therapeutics
Obsidian Therapeutics

Total Raised

$164.5M

Rounds

2

Series B$115MSeptember 2021
quip
quip

Total Raised

$162.2M

Rounds

11

Series B$100MAugust 2021
Ecoatm
Ecoatm

Total Raised

$397.9M

Rounds

9

Private Equity$75MJune 2021